Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 5.53% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 21.85% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -2.55% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -12.57% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -16.45% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 19.16% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 34.19% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 4.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.68% |
| Mar 31, 2026 | 2.30% |
| Dec 31, 2025 | -49.38% |
| Sep 30, 2025 | 113.74% |
| Jun 30, 2025 | 12.41% |
| Mar 31, 2025 | 12.08% |
| Dec 31, 2024 | -6.39% |
| Sep 30, 2024 | 12.43% |
| Jun 30, 2024 | 39.21% |
| Mar 31, 2024 | 35.52% |
| Dec 31, 2023 | 6.27% |
| Sep 30, 2023 | 166.84% |
| Jun 30, 2023 | 13.10% |
| Mar 31, 2023 | 86.99% |
| Dec 31, 2022 | -13.69% |
| Sep 30, 2022 | -35.46% |
| Jun 30, 2022 | 25.05% |
| Mar 31, 2022 | 24.91% |
| Dec 31, 2021 | 14.06% |
| Sep 30, 2021 | -22.74% |